OptimizeRx (NASDAQ:OPRX) Releases Earnings Results, Beats Expectations By $0.04 EPS

OptimizeRx (NASDAQ:OPRX) issued its earnings results on Wednesday. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04, reports. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The business had revenue of $21.61 million during the quarter, compared to analysts’ expectations of $21.19 million.

Here are the key takeaways from OptimizeRx’s conference call:

• OptimizeRx cut its 2026 revenue outlook to $87 million–$93 million, citing customer spending delays and limited visibility into fourth-quarter “buy-ups.” Contracted revenue was about 20% below the comparable prior-year level, increasing the execution risk of meeting the revised range; adjusted EBITDA guidance was maintained at $21 million–$25 million.
• Profitability remained strong despite lower sales: third-quarter revenue fell 17% year over year to $21.6 million, while adjusted EBITDA rose to $6.3 million and margin expanded to about 29% from 20%. Management attributed the improvement to favorable mix, cost reductions, and margin optimization.
• Management cited improving early indicators for 2027, including contracted revenue running about 20% ahead of the comparable point in the prior-year RFP cycle, expanding opportunities in key accounts, and renewed spending from a previously significant customer. Executives said it is too early to provide 2027 guidance, and the returning customer’s spending remains below historical levels.
• Net revenue retention declined to 83%, which management attributed mainly to spending pullbacks at a small number of large accounts rather than broad-based churn. The company is expanding programmatic distribution through DeepIntent, The Trade Desk, and PulsePoint, but said these initiatives are still in the early stages of commercialization.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $8.95 on Thursday. OptimizeRx has a 52 week low of $4.54 and a 52 week high of $16.37. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $168.62 million, a P/E ratio of 38.91 and a beta of 1.20. The stock’s fifty day moving average is $8.43 and its two-hundred day moving average is $7.24.

Analyst Ratings Changes

A number of research firms have recently issued reports on OPRX. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. UBS Group set a $11.00 price objective on OptimizeRx in a research report on Friday, August 14th. B. Riley Financial boosted their price objective on OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. Finally, Weiss Ratings upgraded OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus price target of $11.43.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.